194 related articles for article (PubMed ID: 36785760)
21. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.
Hassel JC; Berking C; Forschner A; Gebhardt C; Heinzerling L; Meier F; Ochsenreither S; Siveke J; Hauschild A; Schadendorf D
Eur J Cancer; 2023 Sep; 191():112986. PubMed ID: 37595494
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
[TBL] [Abstract][Full Text] [Related]
23. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
Klabusay M; Bábková B
Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
[TBL] [Abstract][Full Text] [Related]
24. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract][Full Text] [Related]
25. Evolving Management of Stage IV Melanoma.
Switzer B; Piperno-Neumann S; Lyon J; Buchbinder E; Puzanov I
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e397478. PubMed ID: 37141553
[TBL] [Abstract][Full Text] [Related]
26. Identifying biomarkers and novel therapeutic targets in uveal melanoma.
Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
J Dtsch Dermatol Ges; 2024 Jan; 22(1):29-32. PubMed ID: 37902386
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Goodall HM; Ranade K; Holland C; Abdullah SE; Sacco JJ; Sato T
Nat Med; 2022 Nov; 28(11):2364-2373. PubMed ID: 36229663
[TBL] [Abstract][Full Text] [Related]
28. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
Carvajal RD; Nathan P; Sacco JJ; Orloff M; Hernandez-Aya LF; Yang J; Luke JJ; Butler MO; Stanhope S; Collins L; McAlpine C; Holland C; Abdullah SE; Sato T
J Clin Oncol; 2022 Jun; 40(17):1939-1948. PubMed ID: 35254876
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapies for the Treatment of Uveal Melanoma-History and Future.
Schank TE; Hassel JC
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31344957
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances and Challenges in Uveal Melanoma Immunotherapy.
Fu Y; Xiao W; Mao Y
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804863
[TBL] [Abstract][Full Text] [Related]
31. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
33. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.
Tomsitz D; Ruf T; Heppt M; Staeger R; Ramelyte E; Dummer R; Garzarolli M; Meier F; Meier E; Richly H; Gromke T; Siveke JT; Franklin C; Klespe KC; Mauch C; Kilian T; Seegräber M; Schilling B; French LE; Berking C; Heinzerling L
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444540
[TBL] [Abstract][Full Text] [Related]
34. Tebentafusp in first-line melanoma trials: An outperforming outlier.
Olivier T; Prasad V
Transl Oncol; 2022 Jun; 20():101408. PubMed ID: 35364557
[TBL] [Abstract][Full Text] [Related]
35. Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy.
Orloff M
Ocul Oncol Pathol; 2021 Jun; 7(3):168-176. PubMed ID: 34307327
[TBL] [Abstract][Full Text] [Related]
36. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights.
Rodriguez I; Norman T; Guenther J; Smart K; Kwong A; Berry J; In GK; Worswick S
Clin Exp Dermatol; 2024 Mar; 49(4):392-394. PubMed ID: 37956104
[No Abstract] [Full Text] [Related]
38. First Drug Approved for Rare Eye Cancer.
Cancer Discov; 2022 Apr; 12(4):879-880. PubMed ID: 35115315
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment.
Masaoutis C; Kokkali S; Theocharis S
Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
